AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36028895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin-dependent kinase 4 and 6 inhibitors combined with endocrine therapy
Number of subjects: 56
Study 36028895 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 56
Study 36029028 — intervention group
Group type: EXPERIMENTAL
Intervention: Foundational implementation support (low-touch)
Number of subjects: 170
Study 36029028 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced implementation support (high-touch)
Number of subjects: 170
Study 36029028 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intensification model
Number of subjects: 170
Study 36029527 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-383 (administered intravenously over 1-2 hours once every 3 weeks)
Number of subjects: 124
Study 36029527 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-383 (60 mg dose in dose expansion cohort)
Number of subjects: 124
Study 36029527 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-383 (≥ 40 mg in dose escalation plus dose expansion cohorts)
Number of subjects: 124
Study 36029725 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal exome sequencing (ES) with pharmacogenomics (PGx) results offered as a secondary finding.
Number of subjects: 40
Study 36029725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics (PGx) testing results from fetal exome sequencing.
Number of subjects: 40
Study 36029725 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication administration based on CPIC Level A evidence.
Number of subjects: 40
Study 36030342 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin dispensed to children from age 5
Number of subjects: 0
Study 36030342 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics (including opioids, gabapentinoids, and paracetamol) dispensed to adolescents from age 15
Number of subjects: 0
Study 36030342 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepines and z-hypnotics
Number of subjects: 0
Study 36030342 — intervention group
Group type: COMPARATOR
Intervention: Overall prescription drugs
Number of subjects: 0
Study 36030462 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) combined with gemcitabine/cisplatin
Number of subjects: 31
Study 36030462 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) combined with gemcitabine/carboplatin
Number of subjects: 31
Study 36030576 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane general anesthesia (BS)
Number of subjects: 40
Study 36030576 — intervention group
Group type: EXPERIMENTAL
Intervention: Postictal generalized electroencephalographic suppression (PGES)
Number of subjects: 40
Study 36030576 — intervention group
Group type: EXPERIMENTAL
Intervention: PGES
Number of subjects: 40
Study 36030576 — intervention group
Group type: COMPARATOR
Intervention: BS
Number of subjects: 40
Study 36030593 — intervention group
Group type: EXPERIMENTAL
Intervention: NightWatch intervention
Number of subjects: 41
Study 36030666 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperament and Character Inventory (TCI)
Number of subjects: 570
Study 36030769 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting SpO2 at 90-92%
Number of subjects: 18
Study 36030769 — intervention group
Group type: COMPARATOR
Intervention: Targeting SpO2 at 93-95%
Number of subjects: 18
Study 36030795 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-recent COVID-19 group (>180 days since positive PCR test)
Number of subjects: 501
Study 36030795 — intervention group
Group type: COMPARATOR
Intervention: Control group (serologically negative individuals)
Number of subjects: 501
Study 36031093 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX), median initial dose 9.9 mg/kg
Number of subjects: 38
Study 36031390 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early antiretroviral treatment
Number of subjects: 54
Study 36031390 — intervention group
Group type: COMPARATOR
Intervention: Routine Pneumocystis jirovecii pneumonia prophylaxis
Number of subjects: 54
Study 36031693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (3 courses at baseline, week 24, and week 48)
Number of subjects: 100
Study 36031693 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 courses at baseline, week 24, and week 48)
Number of subjects: 100
Study 36031693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 100
Study 36031693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 36033243 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation for CRRT
Number of subjects: 85000
Study 36033243 — intervention group
Group type: COMPARATOR
Intervention: Systemic heparin anticoagulation for CRRT
Number of subjects: 85000
Study 36033473 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pelvic lymph node dissection (LPND)
Number of subjects: 387
Study 36034306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive treatment with Brainer and physical training with jDome
Number of subjects: 78
Study 36034306 — intervention group
Group type: COMPARATOR
Intervention: Cognitive treatment with Brainer and physical training with a classic bicycle
Number of subjects: 78
Study 36034311 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning system (aEYE) for nystagmus detection
Number of subjects: 0
Study 36034311 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning system (aEYE) validated folds
Number of subjects: 0
Study 36034311 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning system (aEYE) with compressed videos
Number of subjects: 0
Study 36034311 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning system (aEYE) with varying image resolutions
Number of subjects: 0
Study 36034404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension (PH) patients
Number of subjects: 15742
Study 36034404 — intervention group
Group type: COMPARATOR
Intervention: Comparator group (not PH)
Number of subjects: 15742
Study 36034404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial hypertension (largest PH group)
Number of subjects: 15742
Study 36034404 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 PH
Number of subjects: 15742
Study 36034404 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 PH
Number of subjects: 15742
Study 36034404 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 PH
Number of subjects: 15742
Study 36034404 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5 PH
Number of subjects: 15742
Study 36034411 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment (initiating bevacizumab or corticosteroids treatment within three months after RN diagnosis)
Number of subjects: 641
Study 36034411 — intervention group
Group type: COMPARATOR
Intervention: Watch-and-wait policy (no early treatment)
Number of subjects: 641
Study 36034411 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment
Number of subjects: 641
Study 36034445 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c variability
Number of subjects: 0
Study 36034445 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG variability
Number of subjects: 0
Study 36034445 — intervention group
Group type: EXPERIMENTAL
Intervention: Models including FPG variability
Number of subjects: 0
Study 36034894 — intervention group
Group type: EXPERIMENTAL
Intervention: Mango consumption for 8 weeks
Number of subjects: 26
Study 36034912 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietetic-nutritional education program with high prebiotic and probiotic content (dairy and fermented foods, green leafy vegetables, high-fiber fruit, whole grains, etc.)
Number of subjects: 50
Study 36034912 — intervention group
Group type: COMPARATOR
Intervention: Conventional dietary advice from specialized mental health nurses
Number of subjects: 50
Study 36035510 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive subjects
Number of subjects: 0
Study 36035936 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline pulmonary hypertension (mPAP: 21-24 mmHg)
Number of subjects: 344
Study 36035936 — intervention group
Group type: COMPARATOR
Intervention: Non-pulmonary hypertension (mPAP ≤20 mmHg)
Number of subjects: 344
Study 36035936 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 344
Study 36035936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehospitalization
Number of subjects: 344
Study 36035946 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged DAPT (12-24 months)
Number of subjects: 90500
Study 36035946 — intervention group
Group type: COMPARATOR
Intervention: Standard DAPT (6-12 months)
Number of subjects: 90500
Study 36035961 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher magnesium intake (>320 mg/day)
Number of subjects: 4365
Study 36035961 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher magnesium intake (>320 mg/day) in diuretic users
Number of subjects: 4365
Study 36036238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led allergy clinic (Phase 1)
Number of subjects: 466
Study 36036238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led allergy clinic (Phase 2)
Number of subjects: 466
Study 36036238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led allergy clinic (both phases)
Number of subjects: 466
Study 36036294 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 32
Study 36036522 — intervention group
Group type: EXPERIMENTAL
Intervention: Extravascular ICD system
Number of subjects: 356
Study 36036663 — intervention group
Group type: COMPARATOR
Intervention: Fresh solution exchange
Number of subjects: 791
Study 36036663 — intervention group
Group type: EXPERIMENTAL
Intervention: Reuse of original solution
Number of subjects: 791
Study 36036733 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair cortisol concentrations
Number of subjects: 0
Study 36036733 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight changes
Number of subjects: 0
Study 36036829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral 45° head-down position
Number of subjects: 0
Study 36036829 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide pneumoperitoneum
Number of subjects: 0
Study 36036829 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36036877 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-stratified group (RS)
Number of subjects: 87
Study 36036877 — intervention group
Group type: COMPARATOR
Intervention: Standard stratified group (SS)
Number of subjects: 87
Study 36036877 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-stratified group RS4
Number of subjects: 87
Study 36036877 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-stratified groups RS2 and RS3
Number of subjects: 87
Study 36036971 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfollow
Number of subjects: 598
Study 36036971 — intervention group
Group type: EXPERIMENTAL
Intervention: Notification Settings
Number of subjects: 598
Study 36036971 — intervention group
Group type: COMPARATOR
Intervention: Snooze
Number of subjects: 598
Study 36036971 — intervention group
Group type: COMPARATOR
Intervention: Off-Facebook Activity
Number of subjects: 598
Study 36036971 — intervention group
Group type: COMPARATOR
Intervention: Your Time on Facebook
Number of subjects: 598
Study 36036971 — intervention group
Group type: COMPARATOR
Intervention: Set Daily Reminders
Number of subjects: 598
Study 36037056 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-Time Continuous Glucose Monitoring
Number of subjects: 0
Study 36037056 — intervention group
Group type: COMPARATOR
Intervention: Intermittently Scanned Continuous Glucose Monitoring
Number of subjects: 0
Study 36037309 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM-obesity
Number of subjects: 99
Study 36037309 — intervention group
Group type: COMPARATOR
Intervention: obesity
Number of subjects: 99
Study 36037309 — intervention group
Group type: COMPARATOR
Intervention: controls
Number of subjects: 99
Study 36037567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin 3.2 mg/m
Number of subjects: 21
Study 36037722 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (strength or power training) for 12 weeks
Number of subjects: 69
Study 36037722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study 36037793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol awakening response (CAR) measured in saliva samples before (pre-T1) and after (post-T1) the first TKA
Number of subjects: 69
Study 36037793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone (DHEA) secretion measured in saliva samples before (pre-T1) and after (post-T1) the first TKA
Number of subjects: 69
Study 36037793 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar CARauc/Daucawk ratio measured in saliva samples before (pre-T1) and after (post-T1) the first TKA
Number of subjects: 69
Study 36037793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain ratings and the amount of opioid analgesics consumed after the first and second TKAs
Number of subjects: 69
Study 36038116 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitask deep learning model using FAF images
Number of subjects: 1997
Study 36038116 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitask deep learning model using OCT volumes
Number of subjects: 1997
Study 36038116 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitask deep learning model using multimodal (FAF and OCT) data
Number of subjects: 1997
Study 36038628 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive deep brain stimulation (DBS) of the nucleus accumbens (NAc)
Number of subjects: 2
Study 36038633 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy
Number of subjects: 102
Study 36038633 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 102
Study 36038633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 102
Study 36038644 — intervention group
Group type: COMPARATOR
Intervention: Quantitative MRI (T1 relaxation time)
Number of subjects: 101
Study 36038644 — intervention group
Group type: COMPARATOR
Intervention: Quantitative MRI (ECV fraction)
Number of subjects: 101
Study 36038644 — intervention group
Group type: COMPARATOR
Intervention: Quantitative MRI (Fat signal fraction)
Number of subjects: 101
Study 36038644 — intervention group
Group type: COMPARATOR
Intervention: Quantitative MRI (ADC)
Number of subjects: 101
Study 36038644 — intervention group
Group type: COMPARATOR
Intervention: Composite Q-MRI score
Number of subjects: 101
Study 36038699 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L of 0.9% saline over 30 min on two consecutive days
Number of subjects: 14
Study 36038713 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation attempt
Number of subjects: 1512
Study 36038713 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation success prediction score
Number of subjects: 1512
Study 36038713 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of IMV
Number of subjects: 1512
Study 36038713 — intervention group
Group type: EXPERIMENTAL
Intervention: In-ICU mortality
Number of subjects: 1512
Study 36038958 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation management including exercise programs, nutritional support, dysphagia evaluation, and psychological care
Number of subjects: 37
Study 36038958 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation management
Number of subjects: 37
Study 36039153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous difelikefalin (0.5 mcg/kg for up to 64 weeks)
Number of subjects: 848
Study 36039153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 848
Study 36039153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous difelikefalin
Number of subjects: 848
Study 36039372 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media posts from government agency
Number of subjects: 303
Study 36039372 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media posts from near-peer parents
Number of subjects: 303
Study 36039372 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media posts from news media
Number of subjects: 303
Study 36039573 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 3015
Study 36039789 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day low-salt diet (3.0 g/day)
Number of subjects: 124
Study 36039789 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day high-salt diet (18 g/day)
Number of subjects: 124
Study 36039789 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal changes over 14 years
Number of subjects: 124
Study 36039789 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up over 14 years
Number of subjects: 124
Study 36039892 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL), darunavir/ritonavir (DRV/r) and/or etravirine (ETR)
Number of subjects: 257
Study 36039892 — intervention group
Group type: EXPERIMENTAL
Intervention: RAL, DRV/r and/or ETR
Number of subjects: 257
Study 36039910 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-117
Number of subjects: 0
Study 36039920 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire short form 36 (SF36) item 'seldom full of pep'
Number of subjects: 756
Study 36039920 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire short form 36 (SF36) item 'seldom a lot of energy'
Number of subjects: 756
Study 36039920 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire short form 36 (SF36) item 'worn out'
Number of subjects: 756
Study 36039920 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire short form 36 (SF36) item 'seldom happy'
Number of subjects: 756
Study 36040321 — intervention group
Group type: EXPERIMENTAL
Intervention: trifluridine/tipiracil
Number of subjects: 0
Study 36040344 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-calibrated HEI-2010 scores
Number of subjects: 100374
Study 36040345 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized grocery incentive intervention
Number of subjects: 192
Study 36040345 — intervention group
Group type: COMPARATOR
Intervention: BMI <25
Number of subjects: 192
Study 36040345 — intervention group
Group type: COMPARATOR
Intervention: Diet-related medical condition present
Number of subjects: 192
Study 36040352 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturation
Number of subjects: 0
Study 36040352 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and Physical Activity
Number of subjects: 0
Study 36040393 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 1 (low resilience/low adversity-LR/LA)
Number of subjects: 119
Study 36040393 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 2 (low resilience/high adversity-LR/HA)
Number of subjects: 119
Study 36040393 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 3 (high resilience/low adversity-HR/LA)
Number of subjects: 119
Study 36040393 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 4 (high resilience/high adversity-HR/HA)
Number of subjects: 119
Study 36040393 — intervention group
Group type: EXPERIMENTAL
Intervention: HR/LA group
Number of subjects: 119
Study 36040393 — intervention group
Group type: EXPERIMENTAL
Intervention: LR/HA group
Number of subjects: 119
Study 36040393 — intervention group
Group type: EXPERIMENTAL
Intervention: LR/LA and LR/HA groups
Number of subjects: 119
Study 36040501 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 217
Study 36040670 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator support over a 6-month period
Number of subjects: 24
Study 36040767 — intervention group
Group type: EXPERIMENTAL
Intervention: VoiceSense digital voice analysis tool
Number of subjects: 163
Study 36040767 — intervention group
Group type: COMPARATOR
Intervention: Patient Health Questionnaire-9
Number of subjects: 163
Study 36040801 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic stress symptoms
Number of subjects: 236
Study 36040801 — intervention group
Group type: COMPARATOR
Intervention: Trauma-exposed but asymptomatic women
Number of subjects: 236
Study 36040801 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance and re-experiencing symptoms
Number of subjects: 236
Study 36040801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperarousal symptoms
Number of subjects: 236
Study 36040803 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined decrease in apoC-III
Number of subjects: 0
Study 36040803 — intervention group
Group type: COMPARATOR
Intervention: Non-LOF variant participants (control group)
Number of subjects: 0
Study 36040827 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement bundle (patient education flyer, electronic health record order sets with multimodal analgesia regimens, provider education)
Number of subjects: 240
Study 36040827 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement bundle
Number of subjects: 240
Study 36041016 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine-moxifloxacin regimen
Number of subjects: 2516
Study 36041016 — intervention group
Group type: COMPARATOR
Intervention: Control (6-month regimen)
Number of subjects: 2516
Study 36041016 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine-based regimens
Number of subjects: 2516
Study 36041016 — intervention group
Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 2516
Study 36041053 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance Plus (GLB+) intervention
Number of subjects: 0
Study 36041053 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 0
Study 36041061 — intervention group
Group type: COMPARATOR
Intervention: D-mannose 2 g
Number of subjects: 719
Study 36041061 — intervention group
Group type: COMPARATOR
Intervention: D-mannose with herbal supplements
Number of subjects: 719
Study 36041061 — intervention group
Group type: COMPARATOR
Intervention: D-mannose 500 mg plus supplements (N-acetylcysteine and Morinda citrifolia fruit extract)
Number of subjects: 719
Study 36041086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin plus pembrolizumab
Number of subjects: 45
Study 36041227 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical gustometry (CG) assessment
Number of subjects: 45